VEON (NASDAQ:VEON) reported quarterly sales of $2.08 million which missed the analyst consensus estimate of $2.05 billion by 99.90 percent. This is a 99.90 percent decrease over sales of $2.00 billion the same period last year.
Successful Alzheimer’s Data Would Have Placed Roche At Two-Year Competitive Advantage
Before the markets opened on Monday, Roche Holdings AG (OTC:RHHBY) reported disappointing topline results from the Phase III GRADUATE-1 & 2 of…